Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Spinal cancer is caused by spinal tumors that are either primary or metastatic lesions that can involve both the spinal cord and the vertebrae comprising the bony spinal column. Compression of the spinal cord or collapse of the spinal column may result in paralysis, loss of bowel and bladder function, pain, and loss of functional capacity. The cornerstone of treatment for metastatic spinal tumors has been palliation of pain and preservation of neurological function. Conversely, the central tenet of treating primary tumors of the spine, such as chondrosarcomas, sarcomas, and chordomas, along with select oligometastatic lesions, is complete margin-free en bloc resection.
Total en bloc spondylectomy is a surgical technique aimed at achieving en bloc resection of these types of spinal tumors. The total en bloc spondylectomy procedure has one primary goal: to completely and safely remove a spinal tumor and minimize the risk of recurrence. Total en bloc spondylectomy continues to offer promise as a salvage strategy for patients failing treatment with radiation or radiosurgery. Total en bloc spondylectomy is recognized as a very technically challenging surgical procedure that is available at only a few medical centers in the world, including the Stanford Brain Tumor Center.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.